- Home
- EXAI vs CELC Comparison
EXAI vs CELC Comparison
Compare EXAI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAI
- CELC
- Stock Information
- Founded
- EXAI 2012
- CELC 2011
- Country
- EXAI United Kingdom
- CELC United States
- Employees
- EXAI N/A
- CELC N/A
- Industry
- EXAI Biotechnology: Biological Products (No Diagnostic Substances)
- CELC Medical Specialities
- Sector
- EXAI Health Care
- CELC Health Care
- Exchange
- EXAI Nasdaq
- CELC Nasdaq
- Market Cap
- EXAI 613.6M
- CELC 594.7M
- IPO Year
- EXAI 2021
- CELC 2017
- Fundamental
- Price
- EXAI $4.84
- CELC $12.73
- Analyst Decision
- EXAI Hold
- CELC Strong Buy
- Analyst Count
- EXAI 4
- CELC 6
- Target Price
- EXAI $7.00
- CELC $29.17
- AVG Volume (30 Days)
- EXAI 828.8K
- CELC 272.6K
- Earning Date
- EXAI 11-08-2024
- CELC 11-14-2024
- Dividend Yield
- EXAI N/A
- CELC N/A
- EPS Growth
- EXAI N/A
- CELC N/A
- EPS
- EXAI N/A
- CELC N/A
- Revenue
- EXAI $22,877,630.00
- CELC N/A
- Revenue This Year
- EXAI $156.33
- CELC N/A
- Revenue Next Year
- EXAI N/A
- CELC N/A
- P/E Ratio
- EXAI N/A
- CELC N/A
- Revenue Growth
- EXAI N/A
- CELC N/A
- 52 Week Low
- EXAI $3.80
- CELC $11.51
- 52 Week High
- EXAI $7.91
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- EXAI 44.03
- CELC 31.22
- Support Level
- EXAI $4.45
- CELC $12.08
- Resistance Level
- EXAI $4.85
- CELC $13.00
- Average True Range (ATR)
- EXAI 0.38
- CELC 0.94
- MACD
- EXAI -0.07
- CELC -0.32
- Stochastic Oscillator
- EXAI 19.12
- CELC 24.24
About EXAI Exscientia Plc
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.